2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111550
    Bragsin2
    		Inhibitor 99.85%
    Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC50 of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells.
    Bragsin2
  • HY-108539A
    (R)-CE3F4
    		Inhibitor ≥99.0%
    (R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC50 of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC50, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4.
    (R)-CE3F4
  • HY-125873
    KRAS G12C inhibitor 15
    		Inhibitor 98.47%
    KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM.
    KRAS G12C inhibitor 15
  • HY-128590
    PHT-7.3
    		Inhibitor 99.29%
    PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity.
    PHT-7.3
  • HY-128771
    K-Ras G12C-IN-4
    		Inhibitor 99.19%
    K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C.
    K-Ras G12C-IN-4
  • HY-163299
    pan-KRAS-IN-5
    		Inhibitor
    pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 induces cell cycle arrest and promptes apoptosis in KRAS-driven cancer cells.
    pan-KRAS-IN-5
  • HY-163594
    Pan-RAS-IN-3
    		Inhibitor 99.66%
    Pan-RAS-IN-3 is a pan-Ras inhibitor, and can be used for study of melanoma and acute myeloid leukaemia.
    Pan-RAS-IN-3
  • HY-153821
    PROTAC KRAS G12C degrader-2
    		Degrader 98.45%
    PROTAC KRAS G12C degrader-2 (compound 432) is a modulator of K-Ras protein hydrolysis. PROTAC KRAS G12C degrader-2 is a bifunctional compound, which contain on one end a cereblon inhibitor of apoptosis proteins (IAP) and on the other end a moiety which binds KRAS.
    PROTAC KRAS G12C degrader-2
  • HY-120793
    CMC2.24
    		Inhibitor
    CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis.
    CMC2.24
  • HY-114277S
    Sotorasib-d7
    		Inhibitor 98.90%
    Sotorasib-d7 (AMG-510-d7) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC).
    Sotorasib-d<sub>7</sub>
  • HY-I0400R
    N-Acetylneuraminic acid (Standard)
    		Activator
    N-Acetylneuraminic acid (Standard) is the analytical standard of N-Acetylneuraminic acid. This product is intended for research and analytical applications. N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia.
    N-Acetylneuraminic acid (Standard)
  • HY-147229
    GDC-6036-NH
    		Inhibitor 98.06%
    GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a RAS inhibitor and can be used in cancer research.
    GDC-6036-NH
  • HY-111446
    EPAC 5376753
    		Inhibitor 98.10%
    EPAC 5376753 is an allosterically inhibitor of Epac which inhibits Epac1 with an IC50 of 4 µM in Swiss 3T3 cells.
    EPAC 5376753
  • HY-163595
    Pan-RAS-IN-4
    		Inhibitor 98.53%
    Pan-RAS-IN-4 (compound 2) is a potent inhibitor of RAS, with the IC50 of ＜ 100 nM for KRAS G12D. Pan-RAS-IN-4 plays an important rile in cancer research.
    Pan-RAS-IN-4
  • HY-146243
    TH-Z835
    		Inhibitor 99.58%
    TH-Z835 is a mutant selective KRAS (G12D) inhibitor with an IC50 of 1.6 μM. TH-Z835 inhibits both mantGMPPNP/GPPNP exchange and GPPNP/mantGMPPNP exchange.
    TH-Z835
  • HY-156529
    pan-KRAS-IN-2
    		Inhibitor 98.01%
    pan-KRAS-IN-2 (compound 6) is a pan inhibitor of with IC50s ≤10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A, Q61H), and ＞10 μM for KRAS G13D, respectively.
    pan-KRAS-IN-2
  • HY-114277B
    Sotorasib isomer
    		Control 99.09%
    Sotorasib (AMG-510) isomer is the less active isomer of Sotorasib (AMG-510). AMG-510 is a potent KRAS G12C covalent inhibitor.
    Sotorasib isomer
  • HY-157029S
    KRASG12D-IN-1
    		Inhibitor 98.07%
    KRASG12D-IN-1 (compound 22) is a KRASG12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition.
    KRASG12D-IN-1
  • HY-U00417
    ARS-1630
    		Inhibitor 98.10%
    ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
    ARS-1630
  • HY-101796
    NSC-70220
    		Inhibitor 99.42%
    NSC-70220 is a selective and allosteric SOS1 inhibitor. NSC-70220 inhibits allosteric site activation, and partially inhibited catalytic site activation. NSC-70220 has an anticancer effect.
    NSC-70220
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.